SEPTInvestingStart Free

ASPE SCHEDULE 13D: SEC filing

ARCH Venture Fund X, L.P. and affiliated entities

Filed with the SEC on · accession 0001193125-26-454047

ASPE filed a SCHEDULE 13D (schedule 13d) with the SEC on Nov 9, 2026. ARCH Venture Fund X, L.P. and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 3,754,922 shares (12.9%) of Aspen Neuroscience, Inc. common stock following the company's IPO, with the shares resulting from conversion of preferred stock purchased across multiple financing… The stock moved -0.3% by the first close after the filing.

Summary of the filing

ARCH Venture Fund X, L.P. and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 3,754,922 shares (12.9%) of Aspen Neuroscience, Inc. common stock following the company's IPO, with the shares resulting from conversion of preferred stock purchased across multiple financing rounds.

For details, click here →

Key details

Shares of common stock beneficially owned$3.8M
Percentage of class beneficially owned$13
IssuerAspen Neuroscience, Inc.
Reporting person / beneficial ownerARCH Venture Fund X, L.P.
General partner of arch venture fund xARCH Venture Partners X, L.P.
Reporting person / beneficial ownerARCH Venture Fund X Overage, L.P.
Reporting person / beneficial ownerARCH Venture Fund XIV, L.P.
Investment committee member, arch venture partnersRobert Nelsen
Investment committee member, arch venture partnersKeith Crandell
Investment committee member, arch venture partnersKristina Burow
Investment committee member, arch venture partnersSteven Gillis
Investment committee member, arch venture partners xivPaul Berns

How ASPE stock reacted

Close before

$12.44

Nov 6, 2026

First close after

-0.32%

$12.40

5 trading days

—

Since filing

+2.97%

$12.81

✦ Ask GOAX AI about this filing — what it means for ASPE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ASPE?

Click here

Frequently asked questions

What did ASPE file with the SEC on Nov 9, 2026?

ASPE filed a SCHEDULE 13D (SEC filing). ARCH Venture Fund X, L.P. and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 3,754,922 shares (12.9%) of Aspen Neuroscience, Inc. common stock following the company's IPO, with the shares resulting from conversion of preferred stock purchased across multiple financing rounds.

How do I read a SCHEDULE 13D?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D (schedule 13d): A report the company filed with the SEC (the US market regulator).

How did ASPE stock react to this filing?

ASPE closed at $12.44 before the filing and $12.40 on Nov 9, 2026 (-0.32%).

Other ASPE SEC filings

Get alerts when ASPE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ASPE overviewASPE analysisASPE newsLatest SEC filings